TaqMan real time PCR for the Detection of the Gilbert’s Syndrome Markers UGT1A1*28; UGT1A1*36 and UGT1A1*37

被引:0
|
作者
Valentina Daprà
Carla Alliaudi
Ilaria Galliano
Maddalena Dini
Giada Lo Curcio
Cristina Calvi
Marialaura Archetti
Martina Gavatorta
Massimiliano Bergallo
机构
[1] University of Turin,Department of Public Health and Pediatrics, School of Medicine
[2] BioMole srl.,undefined
来源
Molecular Biology Reports | 2021年 / 48卷
关键词
Real time PCR; Gilbert's syndrome; Allelic discrimination; UGT1A1*28; UGT1A1*36; UGT1A1*37; Pharmacogenetics;
D O I
暂无
中图分类号
学科分类号
摘要
Gilbert’s syndrome is characterized by mild unconjugated hyperbilirubinemia. The key of this disease is a diminished activity of UDP-glucuronosyltransferase 1A1 (UGT1A1). TA insertion into the TATA box promoter region of the UGT1A1 gene on chromosome 2 is the genetic basis of Gilbert’s syndrome (UGT1A1*28). An extra TA insert leads to eight (TA)8 repeats (UGT1A1*37) resulting in a further reduction of glucuronidation activity. A variant lacking one TA repeat (TA)5 (UGT1A1*36) has been identified. (TA)8 repeats (UGT1A1*37) and (TA)5 (UGT1A1*36) have been detected in Africans (frequency up to 0.07 and 0.08 respectively). We present a real time PCR method for genotyping the UGT1A1 (TA)n polymorphism (UGT1A1*28, UGT1A1*36, UGT1A1*37) using Taqman PCR on 7500 and cfx96 Real-Time PCR System. We present a real time PCR method for genotyping the UGT1A1 (TA)n polymorphism (UGT1A1*28, UGT1A1*36, UGT1A1*37) using Taqman PCR. About clinical validation, all 53 samples collected from patients referred for suspected Gilbert’s syndrome were analyzed. We found 21 on the 53 patients (39.6%) were homozygotes (UGT1A1-TATA (TA)6) and referred as wild-type, 13 on the 53 patients (24.5%) were homozygotes (UGT1A1-TATA (TA)7) and referred as mutated, 1 on the 53 patients (1.9%) were homozygotes (UGT1A1-TATA (TA)8) and referred as mutated, 1 on the 53 patients (1.9%) were heterozygotes (UGT1A1-TATA (TA)7/8) and referred as mutated, 1 on the 53 patients (1.9%) were heterozygotes (UGT1A1-TATA (TA)5/6) and referred as mutated, and 16 on the 53 patients (30.2%) were heterozygotes (UGT1A1-TATA (TA)6/7). None were homozygotes UGT1A1-TATA (TA)5, homozygotes UGT1A1-TATA (TA)8, or heterozygotes with (TA)5 or (TA)8 alleles. The newly described technique represents a valid alternative method to sequencing, mainly due to its rapidity, easiness, and minor costs.
引用
收藏
页码:4953 / 4959
页数:6
相关论文
共 50 条
  • [41] Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 (FFCD 0504 trial). Results of a planned interim analysis
    Mitry, E.
    Bouche, O.
    Dahan, L.
    Bonnetain, F.
    Laurent-Puig, P.
    Aparicio, T.
    Etienne, P. L.
    Lecaille, C.
    Lafargue, J. P.
    Jouve, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Fei-fei Han
    Chang-long Guo
    Dan Yu
    Jin Zhu
    Li-li Gong
    Guang-run Li
    Ya-li Lv
    He Liu
    Guang-yu An
    Li-hong Liu
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 779 - 788
  • [43] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Han, Fei-fei
    Guo, Chang-long
    Yu, Dan
    Zhu, Jin
    Gong, Li-li
    Li, Guang-run
    Lv, Ya-li
    Liu, He
    An, Guang-yu
    Liu, Li-hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 779 - 788
  • [44] Association of gallstone and polymorphisms of UGT1A1*27 and UGT1A1*28 in patients with hepatitis B virus-related liver failure
    Zhuo, Haiyan
    Fan, Jinhai
    Zhang, Bifeng
    Shi, Yixian
    Zheng, Liqing
    Chai, Yihong
    Yao, Lvfeng
    OPEN MEDICINE, 2022, 17 (01): : 1455 - 1465
  • [45] UGT1A1*6 AND UGT1A1*27 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE NEUTROPENIA IN JAPANESE PATIENTS WITH NSCLC
    Doi, S.
    Nakamura, Y.
    Fukuda, M.
    Takatani, H.
    Fukuda, M.
    Kinoshita, A.
    Soda, H.
    Oka, M.
    Tsukamoto, K.
    Kohno, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 165 - 165
  • [46] Novel missense mutation of the UGT1A1 gene in Thai siblings with Gilbert's syndrome
    Sutomo, R
    Laosombat, V
    Sadewa, AH
    Yokoyama, N
    Nakamura, H
    Matsuo, M
    Nishio, H
    PEDIATRICS INTERNATIONAL, 2002, 44 (04) : 427 - 432
  • [47] Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
    Xu, C-F
    Reck, B. H.
    Xue, Z.
    Huang, L.
    Baker, K. L.
    Chen, M.
    Chen, E. P.
    Ellens, H. E.
    Mooser, V. E.
    Cardon, L. R.
    Spraggs, C. F.
    Pandite, L.
    BRITISH JOURNAL OF CANCER, 2010, 102 (09) : 1371 - 1377
  • [48] Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism
    Gil, Justyna
    Sasiadek, Maria M.
    BIOMARKERS IN MEDICINE, 2012, 6 (02) : 223 - 230
  • [49] Development of UGT1A1 gene polymorphism detection kit
    Mori, Atsuo
    Nakayama, Shinya
    Perrey, Stephane
    Kakihata, Koji
    Ando, Yuichi
    Hasegawa, Yoshinori
    ANNALS OF ONCOLOGY, 2006, 17 : 63 - 63
  • [50] Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert's Syndrome
    Bernabeu, Ignacio
    Marazuela, Monica
    Lucas, Tomas
    Loidi, Lourdes
    Alvarez-Escola, Cristina
    Luque-Ramirez, Manuel
    Fernandez-Rodriguez, Eva
    Paniagua, Amalia-Elisa
    Quinteiro, Celsa
    Casanueva, Felipe F.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05): : 2147 - 2154